Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluvastatin + valsartan
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fluvastatin + valsartan is a fixed-dose combination of two small molecule drugs, fluvastatin and valsartan. Fluvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis, while valsartan is an angiotensin II type 1 receptor blocker (ARB) that reduces blood pressure by blocking the vasoconstrictive effects of angiotensin II. The combination has been studied for its synergistic effects on cardiovascular health, including anti-inflammatory and antioxidative properties, improvement in arterial wall function, reduction in atrial fibrillation burden, and attenuation of atherosclerotic changes. These benefits are observed even at low doses and may extend beyond lipid lowering or blood pressure reduction alone[1][2][3][5].
- Other names
- fluvastatin + valsartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on fluvastatin + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluvastatin + valsartan.